While 503B facilities are required to follow current Good Manufacturing Practices (cGMP), the compounded drugs themselves are not FDA-approved. If semaglutide and tirzepatide are removed from the 503B bulks list, the availability of compounded GLP-1s would drop significantly, Michael Snyder, MD, FACS, FASMBS, DABOM, medical director of the Bariatric Surgery Center at Rose Medical Center, founder and director of the Denver Center for Bariatric Surgery Foundation, and in-house obesity specialist at FuturHealth, told MNT
These seven were further subjected to CDOCKER program, and three of them showed the best potency as DPP-IV inhibitors by possessing binding energy better than vildagliptin
GLP-1 Therapies: Context & Challenge Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are FDA-approved for the treatment of type 2 diabetes and obesity
It is FDA-approved for managing type 2 diabetes and can be prescribed off-label for weight loss
Avoid taking your dose immediately after a very large or greasy meal, as this can increase the likelihood of nausea
Lillys tirzepatide delivered up to 22.5% weight loss in adults with obesity or overweight in SURMOUNT-1, Eli Lilly (2022) There are upcoming changes to your plans drug coverage and we want to be sure youre ready, Aetna (2025) Pharmacy clinical policy bulletins Aetna non-Medicare prescription drug plan, Aetna (2024) Aetna Better Health coverage policy guideline, Aetna (2025) Medicine search tool, Aetna (2025) FDA approves new medication for chronic weight management, U.S